In vitro antiviral activity of dehydroepiandrosterone, 17 synthetic analogs and ERK modulators against herpes simplex virus type 1
In the present study the in vitro antiviral activity of dehydroepiandrosterone (DHEA) and 17 synthetic derivatives against herpes simplex type 1 (HSV-1) was determined. DHEA, epiandrosterone (EA), two synthetic DHEA analogs and three synthetic EA analogs showed a selective inhibitory effect on HSV i...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 20559caa a22018857a 4500 | ||
|---|---|---|---|
| 001 | PAPER-9530 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203928.0 | ||
| 008 | 190411s2012 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-84862240197 | |
| 024 | 7 | |2 cas |a anisomycin, 22862-76-6; epiandrosterone, 481-29-8; mitogen activated protein kinase, 142243-02-5; mitogen activated protein kinase 1, 137632-08-7; prasterone, 53-43-0; Antiviral Agents; Dehydroepiandrosterone, 53-43-0; Viral Proteins | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a ARSRD | ||
| 100 | 1 | |a Torres, N.I. | |
| 245 | 1 | 3 | |a In vitro antiviral activity of dehydroepiandrosterone, 17 synthetic analogs and ERK modulators against herpes simplex virus type 1 |
| 260 | |c 2012 | ||
| 270 | 1 | 0 | |m Wachsman, M.B.; Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Piso 4, 1428 Buenos Aires, Argentina; email: wachsman@qb.fcen.uba.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Acosta, E., Bruttomesso, A., Bisceglia, J., Wachsman, M., Galagovsky, L., Castilla, V., Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro (2008) Virus Res., 135, pp. 203-212 | ||
| 504 | |a Andrade, A., Silva, P., Pereira, A., De Sousa, L., Ferreira, P., Gazzinelli, R., Kroon, E., Bonjardim, C., The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication (2004) Biochem J., 381, pp. 437-446 | ||
| 504 | |a Andrieux, L., Langouët, S., Fautrel, A., Ezan, F., Krauser, J., Savouret, J., Guengerich, F., Guillouzo, A., Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes (2004) Mol. Pharmacol., 65, pp. 934-943 | ||
| 504 | |a Ashida, K., Goto, K., Zhao, Y., Okabe, T., Yanase, T., Takayanagi, R., Nomura, M., Nawata, H., Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase (2005) Biochim. Biophys. Acta, 1728, pp. 84-94 | ||
| 504 | |a Azwa, A., Barton, S., Aspects of herpes simplex virus: a clinical review (2009) J. Fam. Plann. Reprod. Health Care, 35, pp. 237-242 | ||
| 504 | |a Bradley, W., Kraus, L., Good, R., Day, N., Dehydroepiandrosterone inhibits replication of feline immunodeficiency virus in chronically infected cells (1995) Vet. Immunol. Immunopathol., 46, pp. 159-168 | ||
| 504 | |a Cai, Y., Liu, Y., Zhang, X., Suppression of Coronavirus Replication by Inhibition of the MEK Signaling Pathway (2007) J. Virol., 81, pp. 446-456 | ||
| 504 | |a Chambard, J., Lefloch, R., Pouysségur, J., Lenormand, P., ERK implication in cell cycle regulation (2006) Biochim. Biophys. Acta, 1773, pp. 1299-1310 | ||
| 504 | |a Chang, C., Ou, Y., Raung, S., Chen, C., Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection (2005) J. Gen. Virol., 86, pp. 2513-2523 | ||
| 504 | |a Chang, N., Schultz, L., Heath, J., Suppression of IκBα expresión is necessary for c-Jun N-terminal kinase-mediated enhancement of Fas cytotoxicity (2000) Biochem. Biophys. Res. Commun., 274, pp. 4-10 | ||
| 504 | |a Chilukuri, S., Rosen, T., Management of acyclovir-resistant herpes simplex virus (2003) Dermatol. Clin., 21, pp. 311-320 | ||
| 504 | |a Dalla Valle, L., Couet, J., Labrie, Y., Simard, J., Belvedere, P., Simontacchi, C., Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract (1995) Mol. Cell Endocrinol., 111, pp. 83-92 | ||
| 504 | |a Dawson, W., Laverick, L., Morris, M., Tramoutanis, G., Young, L., Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway (2008) J. Virol., 82, pp. 3654-3664 | ||
| 504 | |a Denizot, F., Lang, R., Rapid colorimetric assay for cell growth and survival (1986) J. Immunol. Methods, 89, pp. 271-277 | ||
| 504 | |a Dhawan, P., Bell, A., Kumar, A., Golden, C., Mehta, K., Critical role of p42/44 (MAPK) activation in anisomycin and hepatocyte growth factor-induced LDL receptor expression: activation of Raf-1/MEK-1/p42/44 (MAPK) cascade alone is sufficient to induce LDL receptor expression (1999) J. Lipid Res., 40, pp. 1911-1919 | ||
| 504 | |a Diallo, K., Loemba, H., Oliveira, M., Mavoungou, D., Wainberg, M., Inhibition of human immunodeficiency virus type-1 (HIV-1) replication by immunor (IM28), a new analog of dehydroepiandrosterone (2000) Nucleosides Nucleotides Nucleic Acids, 19, pp. 2019-2024 | ||
| 504 | |a Dokladda, K., Green, K., Pan, D., Hardie, D., PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway (2005) FEBS Lett., 579, pp. 236-240 | ||
| 504 | |a Favata, M., Horiuchi, K., Manos, E., Daulerio, A., Stradley, D., Feeser, W., Van Dyk, D., Trzaskos, J., Identification of a novel inhibitor of mitogen-activated protein kinase (1998) J. Biol. Chem., 273, pp. 18623-18632 | ||
| 504 | |a Field, H., Herpes simplex virus antiviral drug resistance-current trends and future prospects (2001) J. Clin. Virol., 21, pp. 261-269 | ||
| 504 | |a Formoso, G., Chen, H., Kim, J., Montagnani, M., Consoli, A., Quon, M., Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium (2006) Mol. Endocrinol., 20, pp. 1153-1163 | ||
| 504 | |a Freeman, E., Weiss, H., Glynn, J., Cross, P., Whitworth, J., Hayes, R., Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies (2006) AIDS, 20, pp. 73-83 | ||
| 504 | |a Hansen, J., Moore, P., Steitz, T., Structures of Five Antibiotics Bound at the Peptidyl Transferase Center of the Large Ribosomal Subunit (2003) J. Mol. Biol., 330, pp. 1061-1075 | ||
| 504 | |a Hazzalin, C., Le Panse, R., Cano, E., Mahadevan, L., Anisomycin Selectively Desensitizes Signalling Components Involved in Stress Kinase Activation and fos and jun Induction (1998) Mol. Cell Biol., 18, pp. 1844-1854 | ||
| 504 | |a Henderson, E., Schwartz, A., Pashko, L., Abou-Gharbia, M., Swern, D., Dehydroepiandrosterone and 16 alpha-bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes (1981) Carcinogenesis, 2, pp. 683-686 | ||
| 504 | |a Henderson, E., Yang, J., Schwartz, A., Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication (1992) AIDS Res. Hum. Retroviruses, 8, pp. 625-631 | ||
| 504 | |a Hill, C., McKinney, E., Lowndes, C., Munro, H., Murphy, G., Parry, J., Gill, O., The GUM Anon Network, 2009. Epidemiology of herpes simplex virus types 2 and 1 amongst men who have sex with men attending sexual health clinics in England and Wales: implications for HIV prevention and Management Euro Surveill, 14 (47). , http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19418, pii=19418. Available online: <> | ||
| 504 | |a Jiang, Y., Miyazaki, T., Honda, A., Hirayama, T., Yoshida, S., Tanaka, N., Matsuzaki, Y., Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone (2005) J. Gastroenterol., 40, pp. 490-497 | ||
| 504 | |a Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S., Pelletier, G., Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) Endocr. Rev., 24, pp. 152-182 | ||
| 504 | |a Lee, C., Duesbery, N., Highly Selective MEK Inhibitors (2010) Curr. Enzyme Inhib., 6, pp. 146-157 | ||
| 504 | |a Lee, Y., Lee, C., Porcine reproductive and respiratory syndrome virus replication is suppressed by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway (2010) Virus Res., 152, pp. 50-58 | ||
| 504 | |a Liu, D., Iruthayanathan, M., Homan, L., Wang, Y., Yang, L., Wang, Y., Dillon, J., Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms (2007) Endocrinology, 149, pp. 889-898 | ||
| 504 | |a Loria, R., Inge, T., Cook, S., Szakal, A., Regelson, W., Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA) (1988) J. Med. Virol., 26, pp. 301-314 | ||
| 504 | |a Loria, R., Immune up-regulation and tumor apoptosis by androstene steroids (2002) Steroids, 67, pp. 953-966 | ||
| 504 | |a Mavoungou, D., Poaty-Mavoungou, V., Akoume, M., Ongali, B., Mavoungou, E., Inhibition of human immunodeficiency virus type-1 (HIV-1) glycoprotein-mediated cell-cell fusion by immunor (IM28) (2005) Virol. J., 11, pp. 9-10 | ||
| 504 | |a McCubrey, J., Steelman, L., Chappell, W., Abrams, S., Wong, E., Chang, F., Lehmann, B., Franklin, R., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance (2007) Biochim. Biophys. Acta, 1773, pp. 1263-1284 | ||
| 504 | |a Morfin, F., Thouvenot, D., Herpes simplex virus resistance to antiviral drugs (2003) J. Clin. Virol., 26, pp. 29-37 | ||
| 504 | |a Mujugira, A., Magaret Am Baeten, J., Celum, C., Lingappa, J., Risk factors for HSV-2 infection among sexual partners of HSV-2/HIV-1 co-infected persons (2011) BMC Res. Notes, 4, p. 64 | ||
| 504 | |a Newton, R., Cambridge, L., Lorraine, A., Stevens, D., Lindsay, M., Barnes, P., The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1β-dependent PGE 2 release via mechanistically distinct processes (2000) Br. J. Pharmacol., 130, pp. 1353-1361 | ||
| 504 | |a Nguyen, M., Kraft, R., Blaho, J., African green monkey kidney Vero cells require de novo protein synthesis for efficient herpes simplex virus 1-dependent apoptosis (2005) Virology, 336, pp. 274-290 | ||
| 504 | |a Pan, W., Bodempudi, V., Esfandyari, T., Farassati, F., Utilizing Ras Signaling Pathway to Direct Selective Replication of Herpes Simplex Virus-1 (2009) PLoS One, 4 (8), pp. e6514 | ||
| 504 | |a Pedersen, N., North, T., Rigg, R., Reading, C., Higgins, J., Leutenegger, C., Henderson, G., 16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression (2003) Vet. Immunol. Immunopathol., 94, pp. 133-148 | ||
| 504 | |a Perkins, D., Pereira, E., Gober, M., Yarowsky, P., Aurelian, L., The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway (2002) J. Virol., 76, pp. 1435-1449 | ||
| 504 | |a Piret, J., Boivin, G., Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management (2011) Antimicrob. Agents Chemother., 55, pp. 459-472 | ||
| 504 | |a Qin, D., Feng, N., Fan, W., Ma, X., Yan, Q., Lv, Z., Zeng, Y., Lu, C., Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's Sarcoma-associated herpesvirus by herpes simplex virus type 1 (2011) BMC Microbiol., 11, p. 240 | ||
| 504 | |a Ramabhadran, T., Thach, R., Specificity of protein synthesis inhibitors in the inhibition of encephalomyocarditis virus replication (1980) J. Virol., 34, pp. 293-296 | ||
| 504 | |a Romanutti, C., Bruttomesso, A., Bisceglia, J., Castilla, V., Galagovsky, L., Wachsman, M., In vitro antiviral activity of dehydroepiandrosterone and synthetic derivatives against vesicular stomatitis virus (2009) Vet. J., 182, pp. 327-335 | ||
| 504 | |a Romanutti, C., Bruttomesso, A., Castilla, V., Galagovsky, L., Wachsman, M., Anti-adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives (2010) Chemotherapy, 56, pp. 158-165 | ||
| 504 | |a Sharma-Walia, N., Krishnan, H., Naranatt, P., Zeng, L., Smith, M., Chandran, B., ERK1/2 and MEK1/2 Induced by Kaposi's Sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection (2005) J. Virol., 79, pp. 10308-10329 | ||
| 504 | |a Shin, J., Cai, G., Weinberg, A., Leary, J., Levin, M., Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates (2001) J. Clin. Microbiol., 39, pp. 913-917 | ||
| 504 | |a Steiner, I., Kennedy, P., Pachner, A., The neurotropic herpes viruses: herpes simplex and varicella-zoster (2007) Lancet Neurol., 6, pp. 1015-1028 | ||
| 504 | |a Sturgill, T., MAP kinase: it's been longer than fifteen minutes (2008) Biochem. Biophys. Res. Commun., 371, pp. 1-4 | ||
| 504 | |a Talarico, L., Ramirez, J., Galagovsky, L., Wachsman, M., Structure-activity relationship studies in a set of new brassinosteroid derivatives assayed against herpes simples virus type 1 and 2 in cell cultures (2002) Med. Chem. Res., 11, pp. 434-444 | ||
| 504 | |a Talarico, L., Castilla, V., Rámirez, J., Galagovsky, L., Wachsman, M., Synergistic in vitro interactions between (22S,23S)-3-bromo-5,22,23-trihydroxystigmastan-6-one and foscarnet against herpes simples virus type 1 (2006) Chemotherapy, 52, pp. 38-42 | ||
| 504 | |a Van Vollenhoven, R., Dehydroepiandrosterone for the treatment of systemic lupus erythematosus (2002) Expert Opin. Pharmacother., 3, pp. 23-31 | ||
| 504 | |a Wachsman, M., López, E., Ramírez, J., Galagovsky, L., Coto, C., Antiviral effect of brassinosteroids against herpes virus and arena viruses (2000) Antiviral Chem. Chemother., 11, pp. 71-77 | ||
| 504 | |a Wachsman, M., Castilla, V., Talarico, L., Ramirez, J., Galagovsky, L., Coto, C., Antiherpetic mode of action of (22S,23S)-3β-bromo-5α,22,23-trihydroxystigmastan 6-one in-vitro (2004) Int. J. Antimicrob. Agents, 23, pp. 525-527 | ||
| 504 | |a Whitley, R., Roizman, B., Herpes simplex virus infections (2001) Lancet, 357, pp. 1513-1518 | ||
| 504 | |a Zhang, H., Feng, H., Luo, L., Zhou, Q., Luo, Z., Peng, Y., Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2 (2010) Virus Res., 150, pp. 22-27 | ||
| 520 | 3 | |a In the present study the in vitro antiviral activity of dehydroepiandrosterone (DHEA) and 17 synthetic derivatives against herpes simplex type 1 (HSV-1) was determined. DHEA, epiandrosterone (EA), two synthetic DHEA analogs and three synthetic EA analogs showed a selective inhibitory effect on HSV in vitro multiplication. DHEA and E2, a synthetic derivative of EA, were not found to be virucidal to cell-free HSV-1 and did not impair virus adsorption or penetration. We determined that treatment with both compounds decreased viral protein synthesis. Moreover, inhibitory effect of DHEA and E2 on extracellular viral titer was stronger than the inhibition found on total viral infectivity, suggesting that the antiherpetic activity of these compounds may also be in part due to an inhibition in virus formation and release.Since DHEA is a known Raf/MEK/ERK signaling pathway activator, we studied the role of this pathway on HSV-1 infection. ERK1/2 phosphorylation was stimulated in HSV-1 infected cultures. UO126, a Raf/MEK/ERK signaling pathway inhibitor, impaired viral multiplication, while anisomycin, an activator of this pathway, enhanced it.Treatment with DHEA 6. h before infection enhanced HSV-1 multiplication. On the contrary, pre-treatment with E2, which does not modulate Raf/MEK/ERK signaling pathway, did not produce an increase of viral replication. Taking together these results, the antiviral activity of DHEA seems to occur via a mechanism independent of its ability to modulate ERK phosphorylation. © 2012 Elsevier B.V.. |l eng | |
| 536 | |a Detalles de la financiación: Universidad de Buenos Aires, UBACYT 20020090200271 | ||
| 536 | |a Detalles de la financiación: Agencia Nacional de Promoción Científica y Tecnológica, PICT 00985/07 | ||
| 536 | |a Detalles de la financiación: This work was supported by Grants from the Universidad de Buenos Aires, UBA , UBACYT X 505 , UBACYT 20020090200271 and Agencia Nacional de Promoción Científica y Técnica (ANPCYT) PICT 00985/07 . The authors would like to thank Mrs. Claudia Iglesias for English and grammar corrections and Lic. Daniela Orquera for figure improvement. | ||
| 593 | |a Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Piso 4, 1428 Buenos Aires, Argentina | ||
| 593 | |a Departamento de Química Orgánica y UMYMFOR, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Piso 4, 1428 Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a ANTIVIRAL |
| 690 | 1 | 0 | |a DHEA |
| 690 | 1 | 0 | |a DHEA ANALOGS |
| 690 | 1 | 0 | |a ERK |
| 690 | 1 | 0 | |a HERPES SIMPLEX VIRUS |
| 690 | 1 | 0 | |a 16ALPHA BROMO 17,17 ETHYLENDIOXY 5ALPHA ANDROSTAN 3BETA OL |
| 690 | 1 | 0 | |a 16ALPHA BROMO 17,17 ETHYLENDIOXY 5ALPHA ANDROSTAN 3BETA YL ACETATE |
| 690 | 1 | 0 | |a 16ALPHA BROMO 3BETA HYDROXYANDROST 5 EN 17 ONE |
| 690 | 1 | 0 | |a 16ALPHA BROMOEPIANDROSTERONE |
| 690 | 1 | 0 | |a 17 OXO 5ALPHA ANDROSTAN 3BETA YL ACETATE |
| 690 | 1 | 0 | |a 17 OXO 5ALPHA ANDROSTAN 3BETA,16ALPHA DIYL DIACETATE |
| 690 | 1 | 0 | |a 17 OXOANDROST 5 EN 3B,16ALPHA DIYL DIACETATE |
| 690 | 1 | 0 | |a 17 OXOANDROST 5 EN 3B,16BETA YL DIACETATE |
| 690 | 1 | 0 | |a 17 OXOANDROST 5 EN 3BETA YL ACETATE |
| 690 | 1 | 0 | |a 17,17 ETHYLENDIOXY 5ALPHA ANDROST 15 EN 3BETA OL |
| 690 | 1 | 0 | |a 17,17 ETHYLENDIOXY 5ALPHA ANDROSTAN 3BETA YL ACETATE |
| 690 | 1 | 0 | |a 17,17 ETHYLENDIOXYANDROST 5 EN 3B YL ACETATE |
| 690 | 1 | 0 | |a 17,17 ETHYLENDIOXYANDROST 5 EN 3BETA OL |
| 690 | 1 | 0 | |a 3BETA HYDROXY 5ALPHA ANDROST 15 EN 17 ONE |
| 690 | 1 | 0 | |a 3BETA,15ALPHA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE |
| 690 | 1 | 0 | |a 3BETA,15BETA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE |
| 690 | 1 | 0 | |a 3BETA,16ALPHA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE |
| 690 | 1 | 0 | |a 9 (2 HYDROXYETOXYMETYL)GUANINE |
| 690 | 1 | 0 | |a ANISOMYCIN |
| 690 | 1 | 0 | |a ANTIVIRUS AGENT |
| 690 | 1 | 0 | |a EPIANDROSTERONE |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE 1 |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR |
| 690 | 1 | 0 | |a PHOSPHONOFORMIC ACID TRISODIUM SALT HEXAHYDRATE |
| 690 | 1 | 0 | |a PRASTERONE |
| 690 | 1 | 0 | |a RAF PROTEIN |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a UO 126 |
| 690 | 1 | 0 | |a VIRUS PROTEIN |
| 690 | 1 | 0 | |a ANIMAL CELL |
| 690 | 1 | 0 | |a ANTIVIRAL ACTIVITY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DRUG INHIBITION |
| 690 | 1 | 0 | |a DRUG SCREENING |
| 690 | 1 | 0 | |a ENZYME PHOSPHORYLATION |
| 690 | 1 | 0 | |a HERPES SIMPLEX VIRUS 1 |
| 690 | 1 | 0 | |a IN VITRO STUDY |
| 690 | 1 | 0 | |a INHIBITION KINETICS |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a PROTEIN SYNTHESIS INHIBITION |
| 690 | 1 | 0 | |a VIRUS INHIBITION |
| 690 | 1 | 0 | |a VIRUS LOAD |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a ANTIVIRAL AGENTS |
| 690 | 1 | 0 | |a CERCOPITHECUS AETHIOPS |
| 690 | 1 | 0 | |a DEHYDROEPIANDROSTERONE |
| 690 | 1 | 0 | |a HERPESVIRUS 1, HUMAN |
| 690 | 1 | 0 | |a MICROBIAL SENSITIVITY TESTS |
| 690 | 1 | 0 | |a MICROBIAL VIABILITY |
| 690 | 1 | 0 | |a VERO CELLS |
| 690 | 1 | 0 | |a VIRAL LOAD |
| 690 | 1 | 0 | |a VIRAL PROTEINS |
| 690 | 1 | 0 | |a VIRUS REPLICATION |
| 690 | 1 | 0 | |a HERPES |
| 690 | 1 | 0 | |a HUMAN HERPESVIRUS 1 |
| 690 | 1 | 0 | |a SIMPLEXVIRUS |
| 653 | 0 | 0 | |a uo 126 |
| 700 | 1 | |a Castilla, V. | |
| 700 | 1 | |a Bruttomesso, A.C. | |
| 700 | 1 | |a Eiras, J. | |
| 700 | 1 | |a Galagovsky, L.R. | |
| 700 | 1 | |a Wachsman, M.B. | |
| 773 | 0 | |d 2012 |g v. 95 |h pp. 37-48 |k n. 1 |p Antiviral Res. |x 01663542 |w (AR-BaUEN)CENRE-3746 |t Antiviral Research | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862240197&doi=10.1016%2fj.antiviral.2012.05.002&partnerID=40&md5=ef970153d5fe8059e83d30b8684b82ee |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.antiviral.2012.05.002 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_01663542_v95_n1_p37_Torres |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01663542_v95_n1_p37_Torres |y Registro en la Biblioteca Digital |
| 961 | |a paper_01663542_v95_n1_p37_Torres |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 70483 | ||